WO2022014555A1 - 225Ac溶液の製造方法 - Google Patents
225Ac溶液の製造方法 Download PDFInfo
- Publication number
- WO2022014555A1 WO2022014555A1 PCT/JP2021/026222 JP2021026222W WO2022014555A1 WO 2022014555 A1 WO2022014555 A1 WO 2022014555A1 JP 2021026222 W JP2021026222 W JP 2021026222W WO 2022014555 A1 WO2022014555 A1 WO 2022014555A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- solid
- acid
- ions
- phase
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 37
- 239000007790 solid phase Substances 0.000 claims abstract description 148
- 239000007788 liquid Substances 0.000 claims abstract description 65
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 180
- 239000002253 acid Substances 0.000 claims description 101
- 150000002500 ions Chemical class 0.000 claims description 87
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 45
- 239000003480 eluent Substances 0.000 claims description 45
- 229910017604 nitric acid Inorganic materials 0.000 claims description 45
- 229910001426 radium ion Inorganic materials 0.000 claims description 35
- 230000000717 retained effect Effects 0.000 claims description 35
- 238000000746 purification Methods 0.000 claims description 33
- 238000004140 cleaning Methods 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003929 acidic solution Substances 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 4
- 239000011347 resin Substances 0.000 description 40
- 229920005989 resin Polymers 0.000 description 40
- 238000012360 testing method Methods 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 18
- 238000011084 recovery Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 10
- 229910002651 NO3 Inorganic materials 0.000 description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- -1 2-ethylhexyl group Chemical group 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229910052705 radium Inorganic materials 0.000 description 3
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C*(C)O*(C)C*(C)C(N(*)*)=O)C(N(*)*)=O Chemical compound CC(C*(C)O*(C)C*(C)C(N(*)*)=O)C(N(*)*)=O 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 230000005260 alpha ray Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/34—Regenerating or reactivating
- B01J20/345—Regenerating or reactivating using a particular desorbing compound or mixture
- B01J20/3475—Regenerating or reactivating using a particular desorbing compound or mixture in the liquid phase
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B3/00—Extraction of metal compounds from ores or concentrates by wet processes
- C22B3/20—Treatment or purification of solutions, e.g. obtained by leaching
- C22B3/22—Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means, or by thermal decomposition
- C22B3/24—Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means, or by thermal decomposition by adsorption on solid substances, e.g. by extraction with solid resins
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B3/00—Extraction of metal compounds from ores or concentrates by wet processes
- C22B3/20—Treatment or purification of solutions, e.g. obtained by leaching
- C22B3/42—Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B60/00—Obtaining metals of atomic number 87 or higher, i.e. radioactive metals
- C22B60/02—Obtaining thorium, uranium, or other actinides
- C22B60/0295—Obtaining thorium, uranium, or other actinides obtaining other actinides except plutonium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/62—In a cartridge
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/0005—Isotope delivery systems
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
- G21G2001/0089—Actinium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P10/00—Technologies related to metal processing
- Y02P10/20—Recycling
Definitions
- One aspect of the present invention relates to a method for producing a 225 Ac solution.
- RI internal therapy is performed in which a drug containing a radioisotope (RI) is selectively taken into a lesion such as a tumor for treatment.
- RI radioisotope
- alpha rays have a characteristic that the effect of unnecessary exposure to surrounding normal cells is small because the range is short.
- 225 Ac which is one of the alpha ray emitting nuclides, is a radionuclide having a half-life of 10 days, and is expected as a therapeutic nuclide in cancer treatment and the like in recent years.
- Patent Document 1 discloses a method for separating and purifying a 225 Ac component from a solution containing 226 Ra ions and 225 Ac ions, which is obtained by dissolving a 226 Ra target after irradiation.
- One aspect of the present invention is that even if the amount of solvent used for separating 225 Ac ions from a solution containing 226 Ra ions and 225 Ac ions is small (while obtaining a Ra recovery solution having a high 226 Ra concentration), 225.
- a method for producing a 225 Ac solution capable of producing a 225 Ac solution having high Ac purity.
- One aspect of the present invention is a method for producing a 225 Ac solution, which comprises the following steps (I) to (III).
- the solution containing the obtained eluate (2) eluted from the extractant (a) is passed through the solid-phase extraction agent (b) containing the compound represented by the following formula (B) to give 225 Ac ions.
- Step of holding in the solid-phase extractant (b) Step (III): The 225 Ac ion held in the solid-phase extractant (b) is transferred to the solid-phase extractant (b) using an acid-containing eluent (b). eluted from (b), the Ra-Ac solution (1) as compared to 225 Ac purity obtain 225 Ac solution elevated step
- Another aspect of the present invention is a method for producing a 225 Ac solution, which comprises the following steps (Ia) to (IIa).
- Step (IIa): The 225 Ac ions retained in the solid-phase extractant (a) are subjected to the solid-phase 225 Ac ion retained in the solid-phase extractant (a) using an acid-containing eluent (a). Step of elution from extractant (a)
- Another aspect of the present invention is an irradiation step of irradiating a 226 Ra target with at least one selected from charged particles, photons and neutrons to generate 225 Ac by a nuclear reaction.
- 226 Ra ions and 225 Ac ion 225 Ac solution higher from a solution of 225 Ac purity containing can be produced. Further, according to one aspect of the present invention, even if the amount of the solvent used for separating the 225 Ac ion is small (while obtaining a Ra recovery solution having a high 226 Ra concentration), the 226 Ra ion and the 225 Ac ion are contained. 225 Ac solution higher from a solution of 225 Ac purity that can be produced. 225 Ac By using a high purity 225 Ac solution, can be used effectively 225 Ac the desired use, for example, more 225 Ac purity is high, the 226 Ra and less radiopharmaceutical contamination of the daughter nuclide Can be manufactured.
- the solution containing the obtained eluate (2) eluted from the extractant (a) is passed through the solid-phase extraction agent (b) containing the compound represented by the following formula (B) to give 225 Ac ions.
- Step of holding in the solid-phase extractant (b) Step (III): The 225 Ac ion held in the solid-phase extractant (b) is transferred to the solid-phase extractant (b) using an acid-containing eluent (b). eluted from (b), the Ra-Ac solution (1) as compared to 225 Ac purity obtain 225 Ac solution elevated step
- Step (I)> a Ra-Ac solution (1) containing 226 Ra ions and 225 Ac ions is passed through a solid-phase extractant (a) containing a compound represented by the following formula (A), and 225. Ac ions are retained in the solid-phase extractant (a).
- step (I) 225 Ac ions can be retained in the solid-phase extractant (a) and 226 Ra ions that are not retained in the solid-phase extractant (a) can pass through. Since the passing liquid in this step (I) contains most of the 226 Ra ions contained in the Ra-Ac solution (1), it is preferable to recover and reuse this passing liquid. Therefore, the passing liquid in this step (I) is usually a Ra recovery liquid.
- the Ra recovery liquid refers to the passing liquid of the step (I) in the first purification step below, and corresponds to the second step below or the step corresponding to the step (I) in the third and subsequent purification steps which may be further performed. Does not contain the passing liquid.
- the Ra recovery liquid is used, for example, as an electrodeposition liquid or the like for producing a 226 Ra target after undergoing a purification step or the like, if necessary.
- the amount of 226 Ra ions contained in the passing liquid passing through the solid-phase extractant (b) in the following step (II) and the cleaning liquid obtained in the following washing step is usually the amount of 226 Ra ions in the Ra recovery liquid. Since the amount of these passing liquids and cleaning liquids is extremely small, the demerit of diluting the 226 Ra ion concentration is greater than the merit of reusing them, and they are usually discarded without being reused. Therefore, in the present specification, the passing liquid or the cleaning liquid is not referred to as a Ra recovery liquid.
- the solid-phase extractant (a) can selectively retain 225 Ac ions by passing a high-concentration acid (eg, 0.3 M or more in the case of nitric acid), and allows 226 Ra ions to pass through. be able to. As described above, the solid-phase extractant (a) is used for separating 226 Ra ions and 225 Ac ions (the 225 Ac ions are retained in the solid-phase extractant (a) and passed through the 226 Ra ions). Due to the high concentration of acid, less solvent is required to separate 226 Ra and 225 Ac ions.
- a high-concentration acid eg, 0.3 M or more in the case of nitric acid
- this step (I) by using the solid-phase extractant (a), even if the amount of solvent used for separating 225 Ac ions from the solution containing 226 Ra ions and 225 Ac ions is small, 226 Ra ions and 225 Ac ions can be sufficiently separated.
- the Ra-Ac solution (1) is not particularly limited as long as it contains 226 Ra ions and 225 Ac ions, but is preferably a solution containing 226 Ra ions, 225 Ac ions and an acid.
- Preferred examples of an embodiment of the Ra-Ac solution (1) is a 226 Ra target, at least one kind of particles selected from charged particles, photons and neutrons, preferably by dissolving 226 Ra target after irradiation with protons Is the solution obtained.
- 225 Ac is generated through decay or the like in some cases. Therefore, the solution obtained by dissolving the 226 Ra target is a solution containing 226 Ra ions and 225 Ac ions.
- An acid may be used to dissolve the 226 Ra target.
- Examples of the acid include inorganic acids, and examples of the inorganic acids include nitric acid, hydrochloric acid, phosphoric acid, sulfuric acid, boric acid and hydrofluoric acid.
- nitric acid is a substance that can sufficiently dissolve 226 Ra ions and 225 Ac ions, and can efficiently perform separation and purification using solid-phase extractants (a) and (b).
- Hydrochloric acid is preferred, and nitric acid is particularly preferred.
- the acid used in the Ra-Ac solution (1) may be one kind or two or more kinds.
- the acid concentration of the Ra-Ac solution (1) separates 226 Ra and 225 Ac more efficiently when passed through the solid-phase extractant (a) (less 225 Ac passage and 226 Ra retention).
- nitric acid is used as the acid, it is preferably 0.3 M or more, more preferably 0.5 M or more, and preferably 4.0 M or less from the viewpoint of being able to separate).
- hydrochloric acid is used as the acid, the acid concentration in the Ra-Ac solution (1) is preferably 1 M or more, preferably 8 M or less.
- a solvent preferably 10 times or more, more preferably 20 times or more, preferably 50 times or less, more preferably 40 times or less the molar amount of 226 Ra is used.
- the amount of acid used in the above concentration range is preferably 1 mL or more, more preferably 2 mL or more, still more preferably 3 mL or more, preferably 20 mL or less, more preferably 15 mL. Below, it is more preferably 10 mL or less.
- the flow velocity of the Ra-Ac solution (1) when the Ra-Ac solution (1) is passed through the solid-phase extractant (a) is such that 226 Ra and 225 Ac can be separated more efficiently. It is preferably 0.01 mL / min or more, more preferably 0.1 mL / min or more, still more preferably 0.5 mL / min or more, preferably 5 mL / min or less, more preferably 3 mL / min or less, still more preferably. It is 2 mL / min or less.
- the solid-phase extractant (a) is not particularly limited as long as it contains the compound represented by the following formula (A), and may contain conventionally known components contained in the solid-phase extractant.
- the solid-phase extractant (a) may be a solid-phase extractant consisting only of the compound represented by the following formula (A), or the compound represented by the following formula (A) and other components (eg:). Even a solid-phase extract containing a conventionally known additive or an inert support (including a solid-phase extract in which a compound represented by the following formula (A) is introduced into the inert support). good.
- the solid-phase extractant (a) may contain one kind of the compound represented by the following formula (A), or may contain two or more kinds.
- the solid-phase extractant (a) is preferably an inert support containing the compound represented by the following formula (A), and more preferably porous silica or an organic polymer containing the compound represented by the following formula (A).
- the pore diameter of the porous silica is not particularly limited, but is preferably about 50 to 150 ⁇ m.
- Solid phase extraction agent (a) by passing liquid of high concentration of acid, 225 Ac ions can be selectively retained, the low concentration of the acid by liquid passage therein, holding the 225 Ac Ions can be eluted.
- the solid-phase extractant (a) is not particularly limited, but a commercially available product may be used as an example, and examples thereof include "DGA resin” and "DGA branched resin” manufactured by eichrom.
- m and n are independently 0 or 1, and m and n are preferably 1.
- R 1 to R 4 are independently linear or branched alkyl groups having 8 or more and 12 or less carbon atoms. R 1 to R 4 are independent of each other, preferably an octyl group or a 2-ethylhexyl group.
- step (I) the solid phase having 225 Ac ions retained for the purpose of washing away 226 Ra ions that may remain in the solid phase extractant (a).
- a step of cleaning the extractant (a) with a cleaning solution containing an acid a step of cleaning the solid-phase extractant (a) may be performed.
- Examples of the acid used in the washing step of the solid-phase extractant (a) include the same acid as the acid used in the Ra-Ac solution (1), and the preferred acid is also the same.
- the acid used may be one type or two or more types.
- the concentration of the acid is not particularly limited as long as it is a concentration at which the retained 225 Ac ions do not elute, but the concentration is preferably the same as or about the same as that of the Ra-Ac solution (1).
- Step (II) the 225 Ac ions retained in the solid-phase extractant (a) are eluted from the solid-phase extractant (a) using the eluent (a) containing an acid, and the obtained eluate is obtained.
- the liquid containing (2) is passed through a solid-phase extractant (b) containing a compound represented by the following formula (B), and 225 Ac ions are retained in the solid-phase extractant (b).
- step (II) the 225 Ac ions contained in the eluate (2) can be retained in the solid-phase extractant (b) and passed through 226 Ra that can be contained in the eluate (2).
- an acid-containing eluent (a) is used.
- the acid include the same acid as the acid used in the Ra-Ac solution (1), and the preferred acid is also the same.
- the acid used may be one type or two or more types.
- the acid concentration of the eluent (a) is not particularly limited as long as the retained 225 Ac ions can be sufficiently eluted from the solid-phase extractant (a), but the acid used in the eluent (a) is Ra. -When an acid similar to the acid used in the Ac solution (1) is used, it is preferable that the difference in concentration is large.
- the concentration of the acid in the eluent (a) is preferably 0.2 M or less, more preferably 0.1 M or less, still more preferably 0.01 M or less, and the lower limit of the concentration is It suffices if it contains nitric acid, in other words, it is not particularly limited as long as the concentration of nitric acid is larger than 0M.
- the concentration of the acid in the eluent (a) is preferably larger than 0 M and 0.2 M or less.
- the acid used in the Ra-Ac solution (1) may remain in the solid-phase extractant (a), and even in this case, the solid-phase extractant (a) reliably produces 225 Ac ions.
- the concentration of the acid used in the Ra-Ac solution (1) is preferably different from the concentration of the acid in the eluent (a) from the viewpoint of being able to elute the eluate (a). When the concentration of the acid in the above is 1, it is preferably 15 or more.
- the flow rate of the eluent (a) is preferably 0.1 mL / min or more, more preferably 0., from the viewpoint that the retained 225 Ac ions can be sufficiently eluted from the solid-phase extractant (a). It is 5 mL / min or more, preferably 20 mL / min or less, and more preferably 10 mL / min or less.
- the obtained eluate (2) may be passed through the solid-phase extractant (b) as it is, or may be passed through the solid-phase extractant (b) by adjusting the acid concentration, the flow rate, and the like. ..
- 225 Ac ions can be retained in the solid-phase extractant (b).
- the acid concentration of the eluate (2) may not be adjusted.
- the flow velocity when the liquid containing the eluate (2) is passed through the solid-phase extractant (b) is such that 225 Ac ions can be sufficiently retained in the solid-phase extractant (b). It is preferably 1 mL / min or more, more preferably 1.5 mL / min or more, preferably 30 mL / min or less, and more preferably 20 mL / min or less.
- the solid-phase extractant (b) is not particularly limited as long as it contains the compound represented by the following formula (B), and may contain conventionally known components contained in the solid-phase extractant.
- the solid-phase extractant (b) may be a solid-phase extractant consisting only of the compound represented by the following formula (B), or the compound represented by the following formula (B) and other components (eg:). Even a solid-phase extract containing a conventionally known additive or an inert support (including a solid-phase extract in which a compound represented by the following formula (B) is introduced into the inert support). good.
- the solid-phase extractant (b) may contain one kind of compound represented by the following formula (B), or may contain two or more kinds.
- the solid-phase extractant (b) is preferably an inert support containing the compound represented by the following formula (B), and more preferably porous silica or an organic polymer containing the compound represented by the following formula (B).
- the pore diameter of the porous silica is not particularly limited, but is preferably about 50 to 150 ⁇ m.
- Solid phase extraction agent (b) by passing liquid low concentration of acid, it is possible to selectively retain 225 Ac ions, by a high concentration of acid liquid passage therein, holding the 225 Ac Ions can be eluted.
- the solid-phase extractant (b) is not particularly limited, but a commercially available product may be used as an example, and examples thereof include “Ln resin”, “Ln2 resin”, and “Ln3 resin” manufactured by eichrom.
- R 5 and R 6 are independently -R'or -OR'(R'is an alkyl group having 8 carbon atoms).
- the alkyl group having 8 carbon atoms in the R' may be linear or may have a branch, and preferred examples thereof include an octyl group, a 2-ethylhexyl group, and 2-methyl-4,4-. Examples include dimethylpentyl groups.
- Preferable examples of the compound represented by the formula (B) include compounds represented by the following formulas (B-1) to (B-3).
- the cleaning step of the solid-phase extractant (b) is preferably performed separately from the step (II), but the cleaning step of the solid-phase extractant (a) can sufficiently remove 226 Ra ions. If so, the step of passing the liquid containing the eluate (2) through the solid-phase extractant (b) by adjusting the concentration of the eluent (a) and the concentration of the acid in the eluate (2). However, at the same time, the cleaning step of the solid-phase extractant (b) may be performed. In view of such it is possible to obtain a 225 Ac highly pure 225 Ac solution, after the step (II), it is preferable to perform the washing step of solid-phase extraction agent (b).
- Examples of the acid used in the washing step of the solid-phase extractant (b) include the same acid as the acid used in the Ra-Ac solution (1), and the preferred acid is also the same.
- the acid used may be one type or two or more types.
- the concentration of the acid is preferably such that 226 Ra ions are eluted and the retained 225 Ac ions are not eluted, and the acid concentration is higher than that of the solution containing the eluate (2) and the acid concentration is higher than that of the solution containing the eluate (2). It is more preferable that the acid concentration is lower than that of the following eluent (b), and when nitric acid is used as the acid, it is preferably 0.01 M or more, preferably 0.2 M or less.
- the flow rate of the liquid to liquid passage in the washing step of the solid phase extraction agent (b) is, in view of such can be sufficiently eluted 226 Ra ions that may remain in the solid phase extraction agent (b), preferably 0. It is 5 mL / min or more, more preferably 1 mL / min or more, preferably 30 mL / min or less, and more preferably 20 mL / min or less.
- Step (III) In the step (III), the 225 Ac ions retained in the solid-phase extractant (b) are eluted from the solid-phase extractant (b) using the eluent (b) containing an acid, and the Ra-Ac solution is prepared. A 225 Ac solution having a 225 Ac purity higher than that of (1) is obtained.
- an acid-containing eluent (b) is used.
- the acid include the same acid as the acid used in the Ra-Ac solution (1), and the preferred acid is also the same.
- the acid used may be one type or two or more types.
- the acid concentration of the eluent (b) is preferably 0.
- nitric acid is used as the acid, because the retained 225 Ac ions can be sufficiently eluted from the solid-phase extractant (b). It is 2M or more, more preferably 0.3M or more, still more preferably 0.5M or more, preferably 4M or less, more preferably 2M or less, still more preferably 1M or less.
- hydrochloric acid is used as the acid
- the acid concentration of the eluent (b) is preferably 0.3 M or more, preferably 8 M or less.
- the flow rate of the eluent (b) is preferably 0.5 mL / min or more, more preferably 1 mL / min, from the viewpoint that the retained 225 Ac ions can be sufficiently eluted from the solid-phase extractant (b). It is min or more, more preferably 2 mL / min or more, preferably 30 mL / min or less, more preferably 25 mL / min or less, still more preferably 20 mL / min or less.
- the above-mentioned repurification was obtained in the first purification step of obtaining the 225 Ac solution and the first purification step by performing each step including the above-mentioned steps (I) to (III), particularly the above-mentioned other steps. It is preferred to include a second purification step of repurifying the 225 Ac solution.
- the second purification step may be a part of the first purification step, may be the same step as the first purification step, or is a step in which these steps are repeated. You may.
- the 225 Ac solution obtained in the first purification step is used as the same or different solid-phase extractant (a) as the solid-phase extractant (a) used in the first purification step (above).
- the 225 Ac ion retained in the solid-phase extractant (a) is eluted from the solid-phase extractant (a) using an eluent containing an acid, and the 225 Ac solution obtained in the first purification step is obtained.
- the method for producing a 225 Ac solution including such a second purification step is suitable because the acid concentration in the obtained 225 Ac solution is low and the 225 Ac solution can be used as it is for a labeling reaction or the like.
- the 225 Ac solution obtained by elution from the solid-phase extractant (a) as described above is the same as the solid-phase extractant (b) used in the first purification step.
- a liquid is passed through a different solid-phase extractant (b) (a solid-phase extractant (b) containing a compound represented by the above formula (B) ) to retain 225 Ac ions in the solid-phase extractant (b).
- Process and The 225 Ac ion retained in the solid-phase extractant (b) was eluted from the solid-phase extractant (b) using an eluent containing an acid, and the 225 Ac solution obtained in the first purification step was obtained.
- Method for producing 225 Ac solution containing such a second purification step for 225 Ac purity of the resulting 225 Ac solution is high, such as by appropriately adjusting the acid concentration of the 225 Ac solution, the 225 Ac solution When used for labeling reactions and the like, a high labeling rate and a high synthesis yield can be achieved.
- the second purification step preferably further includes a cleaning step of the solid phase extractant (a) and a cleaning step of the solid phase extractant (b), and is the same as the cleaning step performed in the first purification step. It is more preferable to carry out the above step.
- step (Ia) may be performed instead of the above step (I).
- a Ra-Ac solution (1) containing 226 Ra ions and 225 Ac ions is passed through a solid-phase extractant (a) containing a compound represented by the following formula (A1), and 225. Ac ions are retained in the solid-phase extractant (a).
- m and n are 1 independently of each other.
- R 1 to R 4 are independently linear or branched alkyl groups having 8 or more and 12 or less carbon atoms.
- R 1 to R 4 are independent of each other, preferably an octyl group or a 2-ethylhexyl group.
- the Ra-Ac solution (1) used in the step (Ia) a solution having the same composition as the Ra-Ac solution (1) used in the above step (I) can be used and passed through the solid-phase extractant (a).
- the flow rate of the liquid is also the same as that of the Ra-Ac solution (1) used in the above step (I).
- the solid-phase extractant (a) used in the step (Ia) also contains the compound represented by the above formula (A1) instead of the compound represented by the above formula (A), except that the compound represented by the above formula (A1) is contained. ) Is the same as the solid-phase extractant (a).
- the step (IIa) may be performed after the step (Ia) instead of the steps (II) to (III).
- the 225 Ac ions retained in the solid-phase extractant (a) are eluted from the solid-phase extractant (a) using the eluent (a) containing an acid, and the Ra-Ac solution is prepared.
- a 225 Ac solution having a 225 Ac purity higher than that of (1) is obtained.
- the acid-containing eluent (a) used to elute 225 Ac ions from the solid-phase extractant (a) in step (IIa) has the same composition as the eluent (a) used in step (II).
- a solution can be used, and the flow velocity through which the solid-phase extractant (a) is passed is the same as that of the eluent (a) used in the above step (II).
- the method for producing 225 Ac is as follows.
- the details of the irradiation step and the step of obtaining the Ra-Ac solution (1) are as described in the column of the Ra-Ac solution (1).
- the method for producing 225 Ac may further include a step of removing the solvent from the 225 Ac solution and the like.
- the 225 Ac solution may be utilized in the production of a 225 Ac-containing therapeutic agent.
- 225 Ac-containing radionuclide composition obtained by the manufacturing method of this 225 Ac, 225 Ac-containing radionuclide composition to be pharmaceutically acceptable it may be provided.
- this passing liquid corresponds to the Ra recovery liquid
- the DGA resin was washed by passing 20 mL of a 0.7 M nitric acid aqueous solution through the DGA resin after passing the solution (1-1) at a flow rate of 0.8 mL / min (measured value) (DGA resin).
- the cleaning liquid that has passed through the above is also referred to as a cleaning liquid (x)).
- the amount of 225 Ac in the obtained Ra recovery solution and cleaning solution (x) was measured by measuring the radioactivity using a germanium semiconductor detector manufactured by EURISYS MESURES, the amount of 225 Ac was detected by the detector. It was below the limit and 225 Ac could not be detected.
- the following measurement of the amount of radioactive material is a value measured using a similar detector. Further, the result of the amount of 225 Ac in Test Example 1 is an average value obtained by performing the same step three times.
- step (I) in place of 0.7M nitric acid solution 16mL prepared by dissolving 225 Ac, 225 4M aqueous solution of nitric acid was dissolved Ac 20 mL, 225 was dissolved Ac 1M nitric acid aqueous solution 15mL and,, 225 Ac In the same manner as in the above step (I), except that 15 mL of a 0.5 M aqueous nitric acid solution in which (1) was dissolved (the concentration of 225 Ac in each of these solutions was 0.04 to 0.1 MBq / time) was used.
- the amount of 225 Ac in the obtained Ra recovery solution was measured, the amount of 225 Ac was less than the detection limit of the detector when a 4M or 1M aqueous solution of nitrate was used, and a 0.5M aqueous solution of nitrate was used. in this case, 225 Ac amount to 225 Ac amount of 100% was used, was 0.6%.
- step (I) of the test example in place of 0.7M nitric acid aqueous solution of 225 Ac, radioactive concentration of 4M aqueous nitric acid (225 Ac was dissolved 225 Ac is 0.04 ⁇ 0.1MBq / dose ), A 4M aqueous nitric solution was used as the liquid for washing the DGA resin, and 30 mL of water was added to 5 mL of the 0.01M aqueous nitric solution instead of 20mL of the 0.005M aqueous nitric solution in step (II) of Test Example 1 above.
- the amount of 225 Ac in the obtained passing liquid (y) was 100% of the amount of 225 Ac used. It was 0.3%, and the amount of 225 Ac in the DGA resin after passing the 0.01 M aqueous solution of nitrate solution was 1.3% with respect to 100% of the amount of 225 Ac used.
- step (I) in place of 0.7M nitric acid aqueous solution of 225 Ac, using a 0.5M aqueous solution of nitric acid was dissolved 225 Ac (0.04 ⁇ 0.1MBq / dose), DGA
- steps (I) and (II) were carried out in the same manner as above except that a 0.5 M aqueous nitric acid solution was used as the liquid for washing the resin, the amount of 225 Ac in the obtained passing liquid (y) was determined. It was below the detection limit of the detector, and the amount of 225 Ac in the DGA resin after passing the 0.005 M aqueous nitric acid solution was 3.4% with respect to 100% of the amount of 225 Ac used.
- Test Example 5 In the washing step of the solid-phase extractant (b) of Test Example 1, the test was carried out in the same manner as above except that 10 mL of 0.01 M aqueous nitric acid solution was used instead of 10 mL of 0.05 M aqueous nitric acid solution. The amount of 225 Ac in the cleaning solution (z) obtained was below the detection limit of the detector, and 225 Ac could not be detected.
- Test Example 6 When the test was carried out in the same manner as above except that a 1M or 0.5M nitric acid aqueous solution was used instead of the 0.7M nitric acid aqueous solution in the step (III) of Test Example 1, the 1M or 0.5M nitric acid aqueous solution was used. The amount of 225 Ac in the Ln resin after passing the liquid was below the detection limit of the detector, and 225 Ac could not be detected.
- the DGA resin was washed by passing 20 mL of a 0.7 M nitric acid aqueous solution through the DGA resin after passing the solution (1-2) (the washing liquid that passed through the DGA resin is also referred to as a washing liquid (x'). .).
- the amount of 133 Ba in the obtained passing liquid (corresponding to Ra recovery liquid) and cleaning liquid (x') containing 133 Ba was measured, and the amount was 133 Ba.
- the amount of 133 Ba in the obtained passing liquid (corresponding to Ra recovery liquid) and cleaning liquid (x') containing 133 Ba was measured, and the amount was 133 Ba.
- the amount of 133 Ba used was 99.8% with respect to 100% of the amount of 133 Ba used.
- the resulting effluent (y ') was measured 133 Ba content in and wash (z'), 133 Ba amount to 133 Ba amount of 100% was used, was 0.2%. Moreover, when the amount of 133 Ba in the DGA resin after passing the 0.005 M aqueous nitric acid solution was measured, the amount of 133 Ba was below the detection limit of the detector, and 133 Ba could not be detected.
- a passing liquid was obtained by passing 10 mL of a 0.7 M aqueous nitric acid solution through the Ln resin washed with a 0.05 M aqueous nitric acid solution.
- the amount of 133 Ba in the obtained passing liquid was measured, the amount of 133 Ba was below the detection limit of the detector, and 133 Ba could not be detected.
- the amount of 133 Ba in the Ln resin after passing the 0.7 M aqueous nitric acid solution and in the members such as syringes and tubes used in each of the above operations was measured, the amount of 133 Ba was less than the detection limit of the detector. Therefore, 133 Ba could not be detected.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Mechanical Engineering (AREA)
- Geology (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Environmental & Geological Engineering (AREA)
- Metallurgy (AREA)
- Physics & Mathematics (AREA)
- Geochemistry & Mineralogy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- High Energy & Nuclear Physics (AREA)
- Dispersion Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Extraction Or Liquid Replacement (AREA)
- Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
・従来の方法では、得られる225Ac溶液中に、相当量の226Raが残存していることが分かり、得られる225Ac溶液中の225Acの純度の点で、改良の余地があった。
・226Raターゲットから生成される225Acは微量であり、226Raの大部分が未反応のまま残るが、226Raは貴重な核種であること、また、廃棄は容易ではないことから、225Acを分離後の226Ra溶液を回収(以下この回収した液を「Ra回収液」ともいう。)して再利用することが多い。従来の方法では、226Raと225Acとを分離するために大量の溶媒を使用する必要があることが分かり、溶媒の使用量の点やRa回収液の希薄化の点で、改良の余地があった。
工程(I):226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を、下記式(A)で表される化合物を含む固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる工程
工程(II):上記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液(a)を用いて上記固相抽出剤(a)から溶離し、得られた溶出液(2)を含む液を、下記式(B)で表される化合物を含む固相抽出剤(b)に通液し、225Acイオンを該固相抽出剤(b)に保持させる工程
工程(III):上記固相抽出剤(b)に保持された225Acイオンを、酸を含む溶離液(b)を用いて上記固相抽出剤(b)から溶離し、上記Ra-Ac溶液(1)と比べて225Ac純度が高められた225Ac溶液を得る工程
工程(Ia):226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を、下記式(A1)で表される化合物を含む固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる工程
工程(IIa):上記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液(a)を用いて上記固相抽出剤(a)から溶離する工程
上記照射工程で照射された226Raターゲットを酸性溶液に溶解して、226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を得る工程と、
上記225Ac溶液の製造方法を用いて225Ac溶液を得る工程と、
を含む225Acの製造方法である。
また、本発明の一態様によれば、225Acイオンを分離する際に用いる溶媒量が少なくても(226Ra濃度の高いRa回収液を得ながらも)、226Raイオンおよび225Acイオンを含有する溶液から225Ac純度の高い225Ac溶液を製造することができる。
225Ac純度の高い225Ac溶液を用いることで、所望の用途に効率的に225Acを用いることができ、例えば、より225Ac純度が高く、226Raおよびその娘核種の混入が少ない放射性医薬品を製造することができる。
本発明の一態様に係る225Ac溶液の製造方法の一態様は、下記工程(I)~(III)を含む。
工程(I):226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を、下記式(A)で表される化合物を含む固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる工程
工程(II):上記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液(a)を用いて上記固相抽出剤(a)から溶離し、得られた溶出液(2)を含む液を、下記式(B)で表される化合物を含む固相抽出剤(b)に通液し、225Acイオンを該固相抽出剤(b)に保持させる工程
工程(III):上記固相抽出剤(b)に保持された225Acイオンを、酸を含む溶離液(b)を用いて上記固相抽出剤(b)から溶離し、上記Ra-Ac溶液(1)と比べて225Ac純度が高められた225Ac溶液を得る工程
工程(I)では、226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を、下記式(A)で表される化合物を含む固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる。
Ra回収液は、例えば、必要により精製工程等を経た後、226Raターゲットを製造するための電着液等として使用される。
なお、下記工程(II)で固相抽出剤(b)を通過する通過液や、下記洗浄工程で得られる洗浄液に含まれる226Raイオン量は、通常、上記Ra回収液中の226Raイオン量に比べ極めて少ないため、これら通過液や洗浄液は、これらを再利用するメリットよりも、226Raイオン濃度を希釈してしまうデメリットの方が大きく、通常再利用されず廃棄される。このため、本明細書では、該通過液や洗浄液をRa回収液とは言わない。
Ra-Ac溶液(1)は、226Raイオンおよび225Acイオンを含有すれば特に制限されないが、226Raイオン、225Acイオンおよび酸を含む溶液であることが好ましい。
Ra-Ac溶液(1)の一実施態様の好適例は、226Raターゲットに、荷電粒子、光子および中性子から選ばれる少なくとも1種の粒子、好ましくは陽子を照射した後の226Raターゲットを溶解して得られた溶液である。226Raターゲットに粒子を照射することにより、場合により壊変等を経て225Acが生成するため、該226Raターゲットを溶解して得られた溶液は、226Raイオンおよび225Acイオンを含有する溶液となる。なお、226Raターゲットを溶解する際には、酸を用いればよい。
Ra-Ac溶液(1)に用いられる酸は、1種でも、2種以上でもよい。
なお、上記酸として塩酸を用いる場合、Ra-Ac溶液(1)の酸の濃度は、好ましくは1M以上であり、好ましくは8M以下である。
固相抽出剤(a)は、下記式(A)で表される化合物を含めば特に制限されず、固相抽出剤に含まれる従来公知の成分を含んでいてもよい。
固相抽出剤(a)は、下記式(A)で表される化合物のみからなる固相抽出剤であってもよいし、下記式(A)で表される化合物と他の成分(例:従来公知の添加剤、不活性支持体)を含む固相抽出剤(不活性支持体中に下記式(A)で表される化合物が導入されている固相抽出剤も含む)であってもよい。
固相抽出剤(a)は、下記式(A)で表される化合物を1種含んでいてもよく、2種以上含んでいてもよい。
このような固相抽出剤(a)としては特に限定されないが、一例として市販品を用いてもよく、例えば、eichrom社製の「DGAレジン」、「DGAブランチドレジン」が挙げられる。
式(A)中、R1~R4はそれぞれ独立して、炭素数8以上12以下の直鎖または分岐鎖のアルキル基である。R1~R4はそれぞれ独立して、好ましくは、オクチル基または2-エチルへキシル基である。
工程(I)の後、下記工程(II)の前に、例えば、固相抽出剤(a)に残存し得る226Raイオンを洗い流すこと等を目的として、225Acイオンを保持させた上記固相抽出剤(a)を、酸を含む洗浄液を用いて洗浄する工程(固相抽出剤(a)の洗浄工程)を行ってもよい。
該酸の濃度としては、保持された225Acイオンが溶離しない濃度であれば特に限定されないが上記Ra-Ac溶液(1)と同一または同程度の濃度が好ましい。
工程(II)では、上記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液(a)を用いて固相抽出剤(a)から溶離し、得られた溶出液(2)を含む液を、下記式(B)で表される化合物を含む固相抽出剤(b)に通液し、225Acイオンを該固相抽出剤(b)に保持させる。
工程(II)により、溶出液(2)に含まれる225Acイオンを固相抽出剤(b)に保持させ、溶出液(2)に含まれ得る226Raを通過させることができる。
なお、上記酸として塩酸を用いる場合、溶離液(a)の酸の濃度は、好ましくは0Mより大きく、0.2M以下である。
酸の濃度が上記範囲にある溶出液(2)を固相抽出剤(b)に通液することで、225Acイオンを該固相抽出剤(b)に保持させることができるため、得られた溶出液(2)の酸濃度は、調整しなくてもよい。
溶出液(2)を含む液を固相抽出剤(b)に通液する際の流速は、225Acイオンを該固相抽出剤(b)に十分に保持させることができる等の点から、好ましくは1mL/min以上、より好ましくは1.5mL/min以上であり、好ましくは30mL/min以下、より好ましくは20mL/min以下である。
固相抽出剤(b)は、下記式(B)で表される化合物を含めば特に制限されず、固相抽出剤に含まれる従来公知の成分を含んでいてもよい。
固相抽出剤(b)は、下記式(B)で表される化合物のみからなる固相抽出剤であってもよいし、下記式(B)で表される化合物と他の成分(例:従来公知の添加剤、不活性支持体)を含む固相抽出剤(不活性支持体中に下記式(B)で表される化合物が導入されている固相抽出剤も含む)であってもよい。
固相抽出剤(b)は、下記式(B)で表される化合物を1種含んでいてもよく、2種以上含んでいてもよい。
このような固相抽出剤(b)としては特に限定されないが、一例として市販品を用いてもよく、例えば、eichrom社製の「Lnレジン」、「Ln2レジン」「Ln3レジン」が挙げられる。
工程(II)の後、下記工程(III)の前に、例えば、固相抽出剤(b)に残存し得る226Raイオンを洗い流すこと等を目的として、225Acイオンを保持させた上記固相抽出剤(b)を、上記溶出液(2)を含む液よりも酸濃度が高く、かつ、下記溶離液(b)よりも酸濃度が低い酸を用いて洗浄する工程(固相抽出剤(b)の洗浄工程)を行ってもよい。
より225Ac純度の高い225Ac溶液を得ることができる等の点からは、上記工程(II)の後、固相抽出剤(b)の洗浄工程を行うことが好ましい。
該酸の濃度としては、226Raイオンを溶離し、保持された225Acイオンが溶離しないような濃度であることが好ましく、上記溶出液(2)を含む液よりも酸濃度が高く、かつ、下記溶離液(b)よりも酸濃度が低いことがより好ましく、該酸として硝酸を用いる場合、好ましくは0.01M以上であり、好ましくは0.2M以下である。
工程(III)では、固相抽出剤(b)に保持された225Acイオンを、酸を含む溶離液(b)を用いて上記固相抽出剤(b)から溶離し、上記Ra-Ac溶液(1)と比べて225Ac純度が高められた225Ac溶液を得る。
なお、上記酸として塩酸を用いる場合、溶離液(b)の酸の濃度は、好ましくは0.3M以上、好ましくは8M以下である。
再精製を行う場合、固相抽出剤(b)から225Acイオンを溶離させるために用いる酸の濃度と、固相抽出剤(a)に225Acイオンを保持させるために用いる酸の濃度とは、同一であってもよいため、固相抽出剤(b)からの溶出液をそのまま固相抽出剤(a)へ通液させて225Acイオンを保持させることができる。従って、酸の濃度を調整することなく簡便に再精製を行うことができ、さらに225Ac純度の高い225Ac溶液を製造することができる。
該第二の精製工程は、第一の精製工程の一部の工程であってもよいし、第一の精製工程と同様の工程であってもよいし、これらの工程を繰り返し行う工程であってもよい。
該固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液を用いて上記固相抽出剤(a)から溶離し、上記第一の精製工程で得られた225Ac溶液よりも225Ac純度がより高められた225Ac溶液を得る工程と、
を含むことが好ましい。
このような第二の精製工程を含む225Ac溶液の製造方法は、得られる225Ac溶液中の酸濃度が低いので、該225Ac溶液を、標識反応等にそのまま利用できるため好適である。
該固相抽出剤(b)に保持された225Acイオンを、酸を含む溶離液を用いて上記固相抽出剤(b)から溶離し、上記第一の精製工程で得られた225Ac溶液よりも225Ac純度がより高められた225Ac溶液を得る工程と、
を更に含んでもよい。
このような第二の精製工程を含む225Ac溶液の製造方法は、得られる225Ac溶液の225Ac純度が高いため、該225Ac溶液の酸濃度を適宜調節する等により、該225Ac溶液を標識反応等に利用した場合、高い標識率や高い合成収率を達成できる。
本発明の他の一態様では、上記の工程(I)に代えて、工程(Ia)を行ってもよい。工程(Ia)では、226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を、下記式(A1)で表される化合物を含む固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる。
式(A1)中、R1~R4はそれぞれ独立して、炭素数8以上12以下の直鎖または分岐鎖のアルキル基である。R1~R4はそれぞれ独立して、好ましくは、オクチル基または2-エチルへキシル基である。
また、工程(Ia)において用いる固相抽出剤(a)も、上記式(A)で表される化合物の代わりに、上記式(A1)で表される化合物を含む以外は、上記工程(I)で用いる固相抽出剤(a)と同様である。
本発明の他の一態様では、上記の工程(Ia)の後に、上記工程(II)~(III)に代えて、工程(IIa)を行ってもよい。工程(IIa)では、上記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液(a)を用いて固相抽出剤(a)から溶離し、上記Ra-Ac溶液(1)と比べて225Ac純度が高められた225Ac溶液を得る。
本発明の一態様に係る225Acの製造方法は、
226Raターゲットに、荷電粒子、光子および中性子から選ばれる少なくとも1種を照射して核反応により225Acを生成させる照射工程と、
上記照射工程で照射された226Raターゲットを酸性溶液に溶解して、226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を得る工程と、
上記225Ac溶液の製造方法を用いて225Ac溶液を得る工程と、
を含む。
該照射工程およびRa-Ac溶液(1)を得る工程の詳細は、上記Ra-Ac溶液(1)の欄に記載のとおりである。
本発明の一態様に係る225Acの製造方法は、さらに、225Ac溶液から溶媒を除去する工程などを含んでいてもよい。
本発明の一態様において、225Ac溶液は、225Ac含有治療薬の製造に利用されてもよい。また、本発明の一態様においては、この225Acの製造方法によって得られる、薬学的に許容される225Ac含有放射性核種組成物が提供されてもよい。
なお、226Raを用いた試験は、放射能の問題等から容易に行うことができないため、以下では、226Raと同様の結果になると考えられるバリウムを用いて試験を行った。ラジウムは、アルカリ土類金属に属する元素であり、同じくアルカリ土類金属に属し、その中でも質量数が近いバリウムと似た性質を有する。また、かつてウラン抽出後のピッチブレンドからラジウムを抽出する際に、硫酸バリウムとの共沈作用が利用されたことからも、ラジウムとバリウムとは性質が非常に似ていることが知られている。
・工程(I)
225Acイオン(ORNL、オークリッジ国立研究所製)を、60%濃度の硝酸53.3mLを水で1Lにメスアップして調製した溶液に溶解し、0.7M硝酸水溶液(225Acの放射能濃度は0.04~1MBq/回)を調製した。これに更に、Baの質量が30mgとなるように塩化バリウムを溶解させた溶液(1-1)を、固相抽出剤(a)(「DGAレジン」eichrom社製、DGAノーマルレジン、1mLカートリッジ、上記式(A)で表される化合物を含む)に、流速0.8mL/min(実測値)で16mL通液した。この通液により225AcイオンはDGAレジンに保持され、Baを含む通過液(この通過液がRa回収液に相当する)が得られた。
次いで、溶液(1-1)を通液後のDGAレジンに、0.7M硝酸水溶液を、流速0.8mL/min(実測値)で20mL通液することで、DGAレジンを洗浄した(DGAレジンを通過した洗浄液を洗浄液(x)ともいう。)。
また、試験例1における225Ac量の結果は、同様の工程を3回行った平均値である。
0.7M硝酸水溶液で洗浄後のDGAレジンに、0.005M硝酸水溶液を、流速0.8mL/min(実測値)で20mL通液し、225Acイオンを含む溶出液(2-1)を得、得られた溶出液(2-1)を、固相抽出剤(b)(「Lnレジン」eichrom社製、1mLカートリッジ、上記式(B)で表される化合物を含む)に、流速2.5mL/min(実測値)で通液した。この通液により225AcイオンはLnレジンに保持された。この際にLnレジンを通過した通過液を通過液(y)ともいう。
また、0.005M硝酸水溶液を通液後のDGAレジン中の225Ac量を測定したところ、225Ac量の平均値(n=3)は、用いた225Ac量100%に対し、1.6%であった。
次いで、溶出液(2-1)を通液後のLnレジンに、0.05M硝酸水溶液を、流速1mL/min(実測値)で10mL通液し、Lnレジンを洗浄した(Lnレジンを通過した洗浄液を洗浄液(z)ともいう。)。
得られた洗浄液(z)中の225Ac量を測定したところ、225Ac量は検出器の検出限界未満であり、225Acを検出することはできなかった。
0.05M硝酸水溶液で洗浄後のLnレジンに、0.7M硝酸水溶液を、流速2.5mL/min(実測値)で10mL通液し、225Acを含む225Ac溶液を得た。
得られた225Ac溶液中の225Ac量を測定したところ、225Ac量の平均値(n=3)は、用いた225Ac量100%に対し、98.4%であった。
なお、0.7M硝酸水溶液を通液後のLnレジン中、および、上記各操作で用いたシリンジやチューブ等の部材中の225Ac量を測定したところ、225Ac量は検出器の検出限界未満であり、225Acを検出することはできなかった。
上記試験例1の工程(I)において、225Acを溶解した0.7M硝酸水溶液16mLの代わりに、225Acを溶解した4M硝酸水溶液20mL、225Acを溶解した1M硝酸水溶液15mL、または、225Acを溶解した0.5M硝酸水溶液15mL(これら各溶液中の225Acの濃度はいずれも、0.04~0.1MBq/回である。)を用いた以外は、上記工程(I)と同様にして得られたRa回収液中の225Ac量を測定したところ、4Mまたは1M硝酸水溶液を用いた場合には、225Ac量は検出器の検出限界未満であり、0.5M硝酸水溶液を用いた場合には、225Ac量は、用いた225Ac量100%に対し、0.6%であった。
上記試験例1の工程(I)において、225Acを溶解した0.7M硝酸水溶液の代わりに、225Acを溶解した4M硝酸水溶液(225Acの放射能濃度は0.04~0.1MBq/回)を用い、DGAレジンを洗浄する液として、4M硝酸水溶液を用い、上記試験例1の工程(II)において、0.005M硝酸水溶液20mLの代わりに、0.01M硝酸水溶液5mLに水30mLを添加した液を用いた以外は上記と同様にして工程(I)および(II)を行ったところ、得られた通過液(y)中の225Ac量は、用いた225Ac量100%に対し、0.3%であり、0.01M硝酸水溶液を通液後のDGAレジン中の225Ac量は、用いた225Ac量100%に対し、1.3%であった。
上記試験例1の工程(I)において、225Acを溶解した0.7M硝酸水溶液の代わりに、225Acを溶解した0.5M硝酸水溶液(0.04~0.1MBq/回)を用い、DGAレジンを洗浄する液として、0.5M硝酸水溶液を用いた以外は上記と同様にして工程(I)および(II)を行ったところ、得られた通過液(y)中の225Ac量は、検出器の検出限界未満であり、0.005M硝酸水溶液を通液後のDGAレジン中の225Ac量は、用いた225Ac量100%に対し、3.4%であった。
上記試験例1の固相抽出剤(b)の洗浄工程において、0.05M硝酸水溶液10mLの代わりに、0.01M硝酸水溶液10mLを用いた以外は上記と同様にして試験を行ったところ、得られた洗浄液(z)中の225Ac量は検出器の検出限界未満であり、225Acを検出することはできなかった。
上記試験例1の工程(III)において、0.7M硝酸水溶液の代わりに、1Mまたは0.5M硝酸水溶液を用いた以外は上記と同様にして試験を行ったところ、1Mまたは0.5M硝酸水溶液を通液後のLnレジン中の225Ac量は検出器の検出限界未満であり、225Acを検出することはできなかった。
本発明の一態様に係る225Ac溶液の製造方法によってRa-Ac溶液(1)から除去される226Raイオンの挙動を検証するために、以下の実験を行った。なお、226Raイオンの代わりに同様の挙動を示すと考えられる133Baを用いた。
133Baを溶解した0.7M硝酸水溶液(133Baの濃度は0.8MBq/回)に、塩化バリウムを用い、Ba質量が15mgとなるようにBaを溶解させた溶液(1-2)を、固相抽出剤(a)(DGAレジン)に16mL通液した。133Baを含む通過液(この通過液がRa回収液に相当する)が得られた。
次いで、溶液(1-2)を通液後のDGAレジンに、0.7M硝酸水溶液を20mL通液することで、DGAレジンを洗浄した(DGAレジンを通過した洗浄液を洗浄液(x')ともいう。)。
0.7M硝酸水溶液で洗浄後のDGAレジンに、0.005M硝酸水溶液を20mL通液して溶出液(2-2)を得、得られた溶出液(2-2)を、固相抽出剤(b)(Lnレジン)に通液した。この際にLnレジンを通過した通過液を通過液(y')ともいう。
次いで、溶出液(2-2)を通液後のLnレジンを、0.05M硝酸水溶液10mLで洗浄した(Lnレジンを通過した洗浄液を洗浄液(z')ともいう。)。
また、0.005M硝酸水溶液を通液後のDGAレジン中の133Ba量を測定したところ、133Ba量は検出器の検出限界未満であり、133Baを検出することはできなかった。
0.05M硝酸水溶液で洗浄後のLnレジンに、0.7M硝酸水溶液を10mL通液して通過液を得た。
得られた通過液中の133Ba量を測定したところ、133Ba量は検出器の検出限界未満であり、133Baを検出することはできなかった。
なお、0.7M硝酸水溶液を通液後のLnレジン中、および、上記各操作で用いたシリンジやチューブ等の部材中の133Ba量を測定したところ、133Ba量は検出器の検出限界未満であり、133Baを検出することはできなかった。
陽子を照射後の226Raターゲットを溶解して得られた、80μciの226Raおよび0.08μciの225Acを含む0.7M硝酸水溶液を、固相抽出剤(a)(DGAレジン)に5mL通液した。次いで、DGAレジンを0.7M硝酸水溶液20mLで洗浄した。
その後、0.7M硝酸水溶液で洗浄後のDGAレジンに、0.005M硝酸水溶液を20mL通液して225Acを含む溶出液を得た。
得られた溶出液中の226Ra量を測定したところ、226Ra量は0.5μciであり、用いた226Ra量100%に対し、0.6%の226Raが残存していた。
Claims (15)
- 下記工程(I)~(III)を含む、225Ac溶液の製造方法。
工程(I):226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を、下記式(A)で表される化合物を含む固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる工程
工程(II):前記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液(a)を用いて前記固相抽出剤(a)から溶離し、得られた溶出液(2)を含む液を、下記式(B)で表される化合物を含む固相抽出剤(b)に通液し、225Acイオンを該固相抽出剤(b)に保持させる工程
工程(III):前記固相抽出剤(b)に保持された225Acイオンを、酸を含む溶離液(b)を用いて前記固相抽出剤(b)から溶離し、前記Ra-Ac溶液(1)と比べて225Ac純度が高められた225Ac溶液を得る工程
- 前記Ra-Ac溶液(1)が、226Raターゲットに、荷電粒子、光子および中性子から選ばれる少なくとも1種を照射した後の226Raターゲットを溶解して得られた溶液である、請求項1に記載の225Ac溶液の製造方法。
- 前記Ra-Ac溶液(1)が0.3M以上の酸を含む、請求項1または2に記載の225Ac溶液の製造方法。
- 前記工程(I)の後、225Acイオンを保持させた前記固相抽出剤(a)を、酸を含む洗浄液を用いて洗浄してから前記工程(II)を行う、請求項1~3のいずれか1項に記載の225Ac溶液の製造方法。
- 前記工程(II)の後、225Acイオンを保持させた前記固相抽出剤(b)を、前記溶出液(2)を含む液よりも酸濃度が高く、かつ、前記溶離液(b)よりも酸濃度が低い酸を用いて洗浄してから前記工程(III)を行う、請求項1~4のいずれか1項に記載の225Ac溶液の製造方法。
- 前記溶離液(a)の酸濃度よりも前記溶離液(b)の酸濃度が高い、請求項1~5のいずれか1項に記載の225Ac溶液の製造方法。
- 前記溶離液(a)の酸濃度が0.2M以下である、請求項1~6のいずれか1項に記載の225Ac溶液の製造方法。
- 前記溶離液(b)の酸濃度が0.2M以上である、請求項1~7のいずれか1項に記載の225Ac溶液の製造方法。
- 前記溶離液(a)および前記溶離液(b)に含まれる酸が、塩酸、硝酸、リン酸、硫酸、ホウ酸およびフッ化水素酸からなる群より選択される少なくとも1種の無機酸を含む、請求項1~8のいずれか1項に記載の225Ac溶液の製造方法。
- 前記溶離液(a)および前記溶離液(b)に含まれる酸が、塩酸または硝酸を含む、請求項1~9のいずれか1項に記載の225Ac溶液の製造方法。
- 前記工程(III)の後、得られた225Ac溶液を用いて、さらに前記工程(I)~(III)の少なくとも一部を行い、225Ac純度がより高められた225Ac溶液を得る、請求項1~10のいずれか1項に記載の225Ac溶液の製造方法。
- 請求項1~10のいずれか1項に記載の225Ac溶液の製造方法を行い、225Ac溶液を得る第一の精製工程と、
前記第一の精製工程で得られた225Ac溶液を、再精製する第二の精製工程とを含み、
前記第二の精製工程は、前記第一の精製工程で得られた225Ac溶液を、前記第一の精製工程で用いた固相抽出剤(a)と同一または異なる固相抽出剤(a)に通液し、225Acイオンを該固相抽出剤(a)に保持させる工程と、
前記固相抽出剤(a)に保持された225Acイオンを、酸を含む溶離液を用いて前記固相抽出剤(a)から溶離し、前記第一の精製工程で得られた225Ac溶液よりも225Ac純度がより高められた225Ac溶液を得る工程と、
を含む、225Ac溶液の製造方法。 - 前記第二の精製工程で、前記固相抽出剤(a)から溶離して得られた225Ac溶液を、前記第一の精製工程で用いた固相抽出剤(b)と同一または異なる固相抽出剤(b)に通液し、225Acイオンを該固相抽出剤(b)に保持させる工程と、
前記固相抽出剤(b)に保持された225Acイオンを、酸を含む溶離液を用いて前記固相抽出剤(b)から溶離し、前記第一の精製工程で得られた225Ac溶液よりも225Ac純度がより高められた225Ac溶液を得る工程と、
を含む、請求項12に記載の225Ac溶液の製造方法。 - 226Raターゲットに、荷電粒子、光子および中性子から選ばれる少なくとも1種を照射して核反応により225Acを生成させる照射工程と、
前記照射工程で照射された226Raターゲットを酸性溶液に溶解して、226Raイオンおよび225Acイオンを含有するRa-Ac溶液(1)を得る工程と、
請求項1~14のいずれか1項に記載の225Ac溶液の製造方法を用いて225Ac溶液を得る工程と、
を含む225Acの製造方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237001191A KR20230039646A (ko) | 2020-07-17 | 2021-07-13 | 225Ac 용액의 제조 방법 |
EP21842595.7A EP4184528A4 (en) | 2020-07-17 | 2021-07-13 | 225AC SOLUTION PRODUCTION PROCESS |
AU2021309611A AU2021309611A1 (en) | 2020-07-17 | 2021-07-13 | Method for producing 225Ac solution |
CA3189384A CA3189384A1 (en) | 2020-07-17 | 2021-07-13 | Method for producing 225ac solution |
JP2022536364A JPWO2022014555A1 (ja) | 2020-07-17 | 2021-07-13 | |
US18/005,129 US20230310665A1 (en) | 2020-07-17 | 2021-07-13 | Method for producing 225ac solution |
CN202180048807.0A CN115867684A (zh) | 2020-07-17 | 2021-07-13 | 225Ac溶液的制造方法 |
ZA2023/00678A ZA202300678B (en) | 2020-07-17 | 2023-01-16 | Method for producing 225ac solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020123131 | 2020-07-17 | ||
JP2020-123131 | 2020-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022014555A1 true WO2022014555A1 (ja) | 2022-01-20 |
Family
ID=79555512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/026222 WO2022014555A1 (ja) | 2020-07-17 | 2021-07-13 | 225Ac溶液の製造方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230310665A1 (ja) |
EP (1) | EP4184528A4 (ja) |
JP (1) | JPWO2022014555A1 (ja) |
KR (1) | KR20230039646A (ja) |
CN (1) | CN115867684A (ja) |
AU (1) | AU2021309611A1 (ja) |
CA (1) | CA3189384A1 (ja) |
TW (1) | TW202217011A (ja) |
WO (1) | WO2022014555A1 (ja) |
ZA (1) | ZA202300678B (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009527731A (ja) * | 2006-02-21 | 2009-07-30 | アクチニウム ファーマシューティカルズ,インコーポレイティド | 放射線照射226Ra標的から225Acを精製する方法 |
US20150292061A1 (en) * | 2014-04-09 | 2015-10-15 | Los Alamos National Security, Llc | Separation of protactinum, actinium, and other radionuclides from proton irradiated thorium target |
WO2021002275A1 (ja) * | 2019-07-02 | 2021-01-07 | 日本メジフィジックス株式会社 | 226Ra含有溶液の精製方法、226Raターゲットの製造方法および225Acの製造方法 |
-
2021
- 2021-07-13 WO PCT/JP2021/026222 patent/WO2022014555A1/ja unknown
- 2021-07-13 CN CN202180048807.0A patent/CN115867684A/zh active Pending
- 2021-07-13 AU AU2021309611A patent/AU2021309611A1/en active Pending
- 2021-07-13 KR KR1020237001191A patent/KR20230039646A/ko unknown
- 2021-07-13 JP JP2022536364A patent/JPWO2022014555A1/ja active Pending
- 2021-07-13 EP EP21842595.7A patent/EP4184528A4/en active Pending
- 2021-07-13 US US18/005,129 patent/US20230310665A1/en active Pending
- 2021-07-13 CA CA3189384A patent/CA3189384A1/en active Pending
- 2021-07-16 TW TW110126186A patent/TW202217011A/zh unknown
-
2023
- 2023-01-16 ZA ZA2023/00678A patent/ZA202300678B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009527731A (ja) * | 2006-02-21 | 2009-07-30 | アクチニウム ファーマシューティカルズ,インコーポレイティド | 放射線照射226Ra標的から225Acを精製する方法 |
US20150292061A1 (en) * | 2014-04-09 | 2015-10-15 | Los Alamos National Security, Llc | Separation of protactinum, actinium, and other radionuclides from proton irradiated thorium target |
WO2021002275A1 (ja) * | 2019-07-02 | 2021-01-07 | 日本メジフィジックス株式会社 | 226Ra含有溶液の精製方法、226Raターゲットの製造方法および225Acの製造方法 |
Non-Patent Citations (4)
Title |
---|
MAERTENS D., J. MERMANS, S. HEINITZ, T. CARDINAELS: "Ra-226/Ac-225 chemical separation R&D at SCK-CEN", 11TH INTERNATIONAL SYMPOSIUM ON TARGETED ALPHA THERAPY, 4 January 2019 (2019-01-04), XP055947293 |
MCALISTER DANIEL R., HORWITZ E. PHILIP: "Characterization of Extraction of Chromatographic Materials Containing Bis(2‐ethyl‐1‐hexyl)Phosphoric Acid, 2‐Ethyl‐1‐Hexyl (2‐Ethyl‐1‐Hexyl) Phosphonic Acid, and Bis(2,4,4‐Trimethyl‐1‐Pentyl)Phosphinic Acid", SOLVENT EXTRACTION AND ION EXCHANGE, vol. 25, no. 6, 1 October 2007 (2007-10-01), US , pages 757 - 769, XP093065273, ISSN: 0736-6299, DOI: 10.1080/07366290701634594 |
OSTAPENKO, V. ET AL.: "Extraction chromatographic behavior of actinium and REE on DGA, Ln and TRU resins in nitric acid solutions", JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol. 306, 2015, pages 707 - 711, XP035920725, ISSN: 1558-2780, DOI: https://doi.org/10.1007/s10967-015-4331-y * |
See also references of EP4184528A4 |
Also Published As
Publication number | Publication date |
---|---|
ZA202300678B (en) | 2024-05-30 |
TW202217011A (zh) | 2022-05-01 |
EP4184528A1 (en) | 2023-05-24 |
KR20230039646A (ko) | 2023-03-21 |
CN115867684A (zh) | 2023-03-28 |
CA3189384A1 (en) | 2022-01-20 |
EP4184528A4 (en) | 2024-02-14 |
US20230310665A1 (en) | 2023-10-05 |
AU2021309611A1 (en) | 2023-02-16 |
JPWO2022014555A1 (ja) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9951399B2 (en) | Separation of protactinum, actinium, and other radionuclides from proton irradiated thorium target | |
US20230402200A1 (en) | Systems, apparatus and methods for separating actinium, radium, and thorium | |
KR101886883B1 (ko) | 동위원소 제조 방법 | |
Chakravarty et al. | An electro-amalgamation approach to isolate no-carrier-added 177Lu from neutron irradiated Yb for biomedical applications | |
US6716353B1 (en) | Method for preparing high specific activity 177Lu | |
JP5197603B2 (ja) | 種々の供給源からのラジウムの精製方法 | |
EA022498B1 (ru) | Способ получения изотопа | |
KR20040075883A (ko) | 수용액 중의 금속 원소의 이온을 분리하는 방법 및 장치 | |
JP3668191B2 (ja) | 90ストロンチウムから多線量の90yを分離及び精製する方法 | |
EP3430177B1 (en) | Method for isolation of ac from mixture of radium, actinium and thorium | |
Chakravarty et al. | A novel 188W/188Re electrochemical generator with potential for medical applications | |
US20100296616A1 (en) | Methods of producing cesium-131 | |
Narbutt et al. | Gamma emitting radiotracers 224Ra, 212Pb and 212Bi from natural thorium | |
Andris et al. | The development of 126Sn separation procedure by means of TBP resin | |
WO2022014555A1 (ja) | 225Ac溶液の製造方法 | |
Rychkov et al. | Deactivation of the scandium concentrate recovered from uranium leach liquors | |
Van der Meulen et al. | The production of 82Sr using larger format RbCl targets | |
Zona et al. | Wet-chemistry method for the separation of no-carrier-added 211 At/211g Po from 209 Bi target irradiated by alpha-beam in cyclotron | |
Aziz et al. | Radiochemical separation and purification of promethium-149 radioisotope from irradiated of neodymium oxide target (98.4% of 148Nd enrichment) based on extraction chromatography method | |
RU2803641C1 (ru) | Способ получения радиоизотопа тербий-161 | |
CN115094251B (zh) | 放射性裂变产物钼-99的分离方法 | |
WO2022149535A1 (ja) | Ra-226の回収方法、Ra-226溶液の製造方法及びAc-225溶液の製造方法 | |
Misiak et al. | High pure, carrier free 85Sr and 83Rb tracers obtained with AIC-144 cyclotron | |
Chackett et al. | The addition products of heavy-ion bombardment of tantalum | |
Shehata | Radiochemical studies relevant to cyclotron production of the radionuclides 71, 72 As, 68 Ge/68 Ga and 76, 77, 80m Br |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21842595 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022536364 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3189384 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021309611 Country of ref document: AU Date of ref document: 20210713 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021842595 Country of ref document: EP Effective date: 20230217 |